CILP2 and non-small cell lung carcinoma: Our findings revealed that CILP2 was significantly upregulated in the cell lines from breast cancer, neuroblastomas, non-small cell lung cancer, and esophageal cancer, while it was downregulated in the cell lines from the hematopoietic system, such as multiple myeloma, chronic myeloid leukemia, and acute myeloid leukemia (Figure 1C).